ClinicalTrials.gg
Active, not recruitingNCT05092815Updated Aug 8, 2023

The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation

A Phase 2 interventional study of HLX208 in Langerhans Cell Histiocytosis, Erdheim-Chester Disease and LCH, sponsored by Shanghai Henlius Biotech. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-08.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Histiocytosis, Langerhans-Cell with a site in China — 11 open to participants now, 13 under way, 1 of them phase 3. Histiocytosis, Langerhans-Cell · China.

Planned enrollment
11th of 17
25 · median 40
Started
2021
the only one that year
Phase 2
10 of 17
5 open now
Primary completion
2024-06
later than 1 of 12 live
Registered
5th of 17
by date
Lead sponsor
1 of 17
Shanghai Henlius Biotech

Among the 17 studies in Histiocytosis, Langerhans-Cell with a site in China, this one is the 11th largest by planned enrollment, is the only one that started in 2021, is one of 10 in phase 2, reaches primary completion later than 1 of the 12 other live ones, and was the 5th registered.

Histiocytosis, Langerhans-Cell

81 studies on the registry are indexed under Histiocytosis, Langerhans-Cell; 23 are open to participants now.

Browse Histiocytosis, Langerhans-Cell studies →

Open to participants now

11 of the 17 studies in Histiocytosis, Langerhans-Cell with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 19 Histiocytosis, Langerhans-Cell studies recruiting now, 8 (42%) set no upper age limit and 10 (53%) stop at 75 or younger; 13 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Histiocytosis, Langerhans-Cell with a site in China, or all of them as a file.
02

Study summary

The purpose of this study was to assess safety, efficacy and PK in adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) given HLX208 (BRAF V600E inhibitor).

03

Conditions studied

  • Langerhans Cell Histiocytosis
  • Erdheim-Chester Disease
  • LCH
  • ECD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Volunteer to participate in the clinical study;
  2. Aged ≥ 18 years;
  3. Confirmed adult patients with LCH and/or ECD with BRAF V600E mutation;
  4. At least one as per PERCIST v1.0;
  5. Expected survival time ≥ 3 months;
  6. score 0-2;

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment with BRAF inhibitors or MEK inhibitors;
  2. A history of other within two years, except for cured cervical carcinoma in situ, basal cell carcinoma of the skin, adenocarcinoma in situ of the lung, or tumors that do not require interventional treatment after radical surgery;
  3. Severe active infections requiring systemic anti-infective therapy;
  4. Other anti-tumor treatments, such as chemotherapy, targeted therapy, or radiation therapy (except palliative radiation therapy), may be given during the study period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    HLX208

    Participants receive HLX208 450mg bid po

    Drug: HLX208

Interventions

  • DrugHLX208

    HLX208 450mg bid po

    Also known as: BRAF V600E inhibitor

06

What researchers measure

Primary outcomes

  1. ORR

    Objective response rate(assessed by independent review committee (IRC) based on the PERCIST Version 1.0)

    Time frame: up to 1 year

Secondary outcomes

  1. AEs

    Incidence and severity of adverse events

    Time frame: up to 1 year

  2. ORR

    Objective response rate(assessed by the investigator based on the PERCIST v1.0)

    Time frame: up to 1 year

  3. ORR

    Objective response rate(assessed by IRC and the investigator based on the RECIST v1.1)

    Time frame: up to 1 year

  4. DCR

    Disease control rate (assessed by IRC and the investigator as per PERCIST v1.0 and RECIST v1.1 )

    Time frame: up to 1 year

  5. TTR

    Time to response(assessed by IRC and the investigator as per PERCIST v1.0 and RECIST v1.1)

    Time frame: up to 1 year

  6. PFS

    Progression-free survival (PFS) (assessed by IRC and the investigator as per PERCIST v1.0 and RECIST v1.1 )

    Time frame: from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 1 year

  7. OS

    Overall survival

    Time frame: from the date of first dose until the date of death from any cause,assessed up to 1 year

  8. Cmax

    Maximum Plasma Concentration

    Time frame: from the date of first dose to 85 days

  9. Tmax

    Time of Maximum Plasma Concentration

    Time frame: from the date of first dose to 85 days

  10. AUC

    Area Under the Curve

    Time frame: from the date of first dose to 85 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Jun 2024, 30 months after the start.

Of 32 phase 2 interventional studies under Histiocytosis, Langerhans-Cell, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 85. This study's planned 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2021
First posted
Oct 26, 2021
StartActual
Dec 6, 2021
Primary completionEst.
Jun 30, 2024
CompletionEst.
Oct 30, 2024
Last update
Aug 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05092815
Responsible party
Sponsor
First posted
Oct 26, 2021
Start date
Dec 6, 2021
Primary completion
Jun 30, 2024 (estimated)
Completion
Oct 30, 2024 (estimated)
Last update
Aug 8, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BRAF V600E Inhibitor HLX208

Start the discussion